Role of Ovarian Suppression in Early Premenopausal Breast Cancer
Author(s)
Francis, PA;
Details
Publication Year 2023-02,Volume 37,Issue #1,Page 79-88
Journal Title
Hematology/Oncology Clinics of North America
Publication Type
Review
Abstract
The benefit from removing ovaries to control premenopausal breast cancer growth was identified more than 100 years ago. Subsequent identification of estrogen receptor (ER) enabled targeting of this approach. Development of gonadotropin-releasing hormone agonists facilitated a reversible method of ovarian function suppression, suitable for young women with early breast cancer. Clinical trials have established the value of including ovarian suppression to reduce recurrence of ER-positive premenopausal early breast cancer. Ovarian suppression administered with chemotherapy can reduce the risk of premature menopause in ER-negative cancer, and increase the prospect of future pregnancy in premenopausal women, regardless of tumor hormone receptor status.
Publisher
Elsevier
Keywords
Female; Humans; *Ovary/pathology; *Breast Neoplasms/drug therapy/pathology; Premenopause; Adjuvant endocrine therapy; Early breast cancer; Estrogen receptor-positive; Ovarian suppression
Department(s)
Medical Oncology
PubMed ID
36435615
Open Access at Publisher's Site
10.1016/j.hoc.2022.08.006
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-04-06 06:53:47
Last Modified: 2024-07-10 06:36:39

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙